Literature DB >> 17606927

Insulin-like growth factor binding protein 2 promotes glioma development and progression.

Sarah M Dunlap1, Joseph Celestino, Hua Wang, Rongcai Jiang, Eric C Holland, Gregory N Fuller, Wei Zhang.   

Abstract

Overexpression of insulin-like growth factor binding protein 2 (IGFBP2) is associated with progression in many types of human cancer. In this study we used a glial-specific transgenic mouse model to examine the active role of IGFBP2 in tumorigenesis and progression. Our studies show that IGFBP2 coexpression results in progression to a higher-grade glioma in platelet-derived growth factor beta (PDGFB)-driven tumors. These anaplastic oligodendrogliomas are characterized by increased cellularity, vascular proliferation, small regions of necrosis, increased mitotic activity, and increased activation of the Akt pathway. Combined expression of IGFBP2 or Akt with K-Ras was required to form astrocytomas, indicating that activation of two separate pathways is necessary for gliomagenesis. In ex vivo experiments, blockade of Akt by an inhibitor led to decreased viability of cells coexpressing IGFBP2 versus PDGFB expression alone. Thus, this study provides definitive evidence that IGFBP2 plays a key role in activation of the Akt pathway and collaborates with K-Ras or PDGFB in the development and progression of two major types of glioma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606927      PMCID: PMC1913900          DOI: 10.1073/pnas.0703145104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia.

Authors:  K L Mohnike; U Kluba; U Mittler; V Aumann; P Vorwerk; W F Blum
Journal:  Eur J Pediatr       Date:  1996-02       Impact factor: 3.183

2.  Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors.

Authors:  N Boulle; A Logié; C Gicquel; L Perin; Y Le Bouc
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

3.  Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor.

Authors:  A Flyvbjerg; O Mogensen; B Mogensen; O S Nielsen
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

4.  Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice.

Authors:  E C Holland; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

5.  Somatic mutations of PTEN in glioblastoma multiforme.

Authors:  S I Wang; J Puc; J Li; J N Bruce; P Cairns; D Sidransky; R Parsons
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

6.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

7.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.

Authors:  K Podsypanina; L H Ellenson; A Nemes; J Gu; M Tamura; K M Yamada; C Cordon-Cardo; G Catoretti; P E Fisher; R Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.

Authors:  A Suzuki; J L de la Pompa; V Stambolic; A J Elia; T Sasaki; I del Barco Barrantes; A Ho; A Wakeham; A Itie; W Khoo; M Fukumoto; T W Mak
Journal:  Curr Biol       Date:  1998-10-22       Impact factor: 10.834

9.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

10.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice.

Authors:  E C Holland; W P Hively; R A DePinho; H E Varmus
Journal:  Genes Dev       Date:  1998-12-01       Impact factor: 11.361

View more
  64 in total

1.  Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Authors:  Ling-Yuan Kong; Adam S Wu; Tiffany Doucette; Jun Wei; Waldemar Priebe; Gregory N Fuller; Wei Qiao; Raymond Sawaya; Ganesh Rao; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

2.  STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.

Authors:  Vassiliki Kotoula; Sofia Lambaki; Despina Televantou; Anna Kalogera-Fountzila; Angelos Nikolaou; Konstantinos Markou; Despina Misailidou; Konstantinos N Syrigos; George Fountzilas
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

3.  Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.

Authors:  Mary Jo Fidler; David D Shersher; Jeffrey A Borgia; Philip Bonomi
Journal:  Ther Adv Med Oncol       Date:  2012-03       Impact factor: 8.168

Review 4.  Defining the pathway to insulin-like growth factor system targeting in cancer.

Authors:  Steven A Rosenzweig; Hanudatta S Atreya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

5.  Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20.

Authors:  Gianluca Marucci; Luca Morandi; Elisabetta Magrini; Anna Farnedi; Enrico Franceschi; Rossella Miglio; Daniela Calò; Annalisa Pession; Maria P Foschini; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2008-10-25       Impact factor: 4.064

6.  Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping.

Authors:  Robert J Higgins; Peter J Dickinson; Richard A LeCouteur; Andrew W Bollen; Huamin Wang; Hua Wang; Linda J Corely; Lynnette M Moore; Wei Zang; Gregory N Fuller
Journal:  J Neurooncol       Date:  2009-12-05       Impact factor: 4.130

7.  Ionizing radiation and glioblastoma exosomes: implications in tumor biology and cell migration.

Authors:  W Tris Arscott; Anita T Tandle; Shuping Zhao; Jacob E Shabason; Ira K Gordon; Cody D Schlaff; Guofeng Zhang; Philip J Tofilon; Kevin A Camphausen
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

8.  Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers.

Authors:  Jonathan M Dreyfuss; Mark D Johnson; Peter J Park
Journal:  Mol Cancer       Date:  2009-09-04       Impact factor: 27.401

9.  Astrocytes derived from trisomic human embryonic stem cells express markers of astrocytic cancer cells and premalignant stem-like progenitors.

Authors:  Sailesh Gopalakrishna-Pillai; Linda E Iverson
Journal:  BMC Med Genomics       Date:  2010-04-27       Impact factor: 3.063

10.  PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions.

Authors:  Kenichi Miyako; Laura J Cobb; Malik Francis; Alden Huang; Bonnie Peng; John E Pintar; Hiroyoshi Ariga; Pinchas Cohen
Journal:  Mol Endocrinol       Date:  2008-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.